Intervet Inc.

934 4305

RECEIVED

TENTRAL FAX CENTER
P. 1

MAP (1.5.2000)

Telefax Transmittal Cover sheet



Intervet Inc. 405 State Street P.O. Box 318 Millsboro, DE 19966 (302) 934-8051

March 5, 2004

7...pages including cover sheet.

 PERSON TO:
 COMPANY/DEPT TO:
 FAX NUMBER:

 Ex. Nolan
 USPTO
 703 972 9306

 Art Unit 1644
 Art Unit 1644

PERSON FROM:	COMPANY/DEPT FROM:	FAX NUMBER:

William P. Ramey, III

Akzo Nobel Pharma

302-934-4305

Patent Department

Please accept the following response to the Final Office Action of December 19, 2003.

Response – 6 pages Cover sheet – 1 page

Cintervet

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED, AND MAY CONTAIN PROPRIETARY INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND EXEMPT FROM DISCLOSURE UNDER APPLICABLE LAW. IF YOU ARE NOT THE ADDRESSEE, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION, OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, NOTIFY US IMMEDIATELY BY TELEPHONE (COLLECT). THANK YOU.

PTO/SB/97 (08-03)
Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

# Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office

Signature

Typed or printed name of person signing Cortificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

This collection of Information is required by 37 CFR 1.8. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.8 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

RECEIVED

DENTRAL FAX DENTER

MAR 0.5 7096

Atty Docket No.: O/96198 US-D1

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

BOOTS ET AL.

Serial No.: 09/657,757

Group Art Unit: 1644

Filed: September 8, 2000

Examiner: Nolan, P.

For: NOVEL PEPTIDES SUITABLE FOR USE IN ANTIGEN SPECIFIC IMMUNO-

SUPPRESSIVE THERAPY

Assistant Commissioner of Patents Arlington, VA 22313

Dear Sir:

#### RESPONSE TO FINAL OFFICE ACTION OF

### **DECEMBER 19, 2003 PURSUANT TO 37 CFR §1.116**

#### I. INTRODUCTION

Applicants respectfully respond to the final office action of December 19, 2003, as follows. Please charge any required fees and credit any credits to deposit account 02-2334. This response should be entered as it only Claims indicated allowable subject matter and/or removes issues for appeal, pursuant to 37 CFR §1.116.